• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19.HIV-1 感染者住院治疗 COVID-19 时，中和抗体针对 I 型干扰素的频率较高。
Clin Immunol. 2022 Aug;241:109068. doi: 10.1016/j.clim.2022.109068. Epub 2022 Jun 25.
2
Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity.来自 COVID-19 患者的抗 IFN-α/-ω 中和抗体与 IFN 反应下调和疾病严重程度的实验室生物标志物相关。
Eur J Immunol. 2022 Jul;52(7):1120-1128. doi: 10.1002/eji.202249824. Epub 2022 Apr 28.
3
Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.早期快速识别中和型 I 型干扰素自身抗体阳性的 COVID-19 患者。
J Clin Immunol. 2022 Aug;42(6):1111-1129. doi: 10.1007/s10875-022-01252-2. Epub 2022 May 5.
4
[Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].[新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2病毒脱落情况及中和抗体水平]
Mikrobiyol Bul. 2022 Jul;56(3):416-431. doi: 10.5578/mb.20229704.
5
Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.自身免疫性多内分泌腺综合征 1 型患者存在针对 I 型干扰素的自身抗体，但仍为轻症 COVID-19。
J Clin Invest. 2021 Jul 15;131(14). doi: 10.1172/JCI150867.
6
Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai.上海多中心重症或危重症 COVID-19 病例队列中抗 I 型干扰素中和自身抗体的流行情况
J Clin Immunol. 2024 Mar 10;44(3):80. doi: 10.1007/s10875-024-01683-z.
7
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.一项对 SARS-CoV-2 感染患者的纵向研究表明，中和抗体与 COVID-19 严重程度之间存在高度相关性。
Cell Mol Immunol. 2021 Feb;18(2):318-327. doi: 10.1038/s41423-020-00588-2. Epub 2021 Jan 6.
8
Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.在西班牙马德里住院的重症 COVID-19 肺炎患者中，有>10%的患者存在针对 I 型 IFNs 的中和自身抗体。
J Clin Immunol. 2021 Jul;41(5):914-922. doi: 10.1007/s10875-021-01036-0. Epub 2021 Apr 13.
9
High neutralizing antibody titer in intensive care unit patients with COVID-19.COVID-19 重症监护病房患者的高中和抗体滴度。
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670. doi: 10.1080/22221751.2020.1791738.
10
Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan.SARS-CoV-2 感染后的纵向中和抗体反应：台湾的康复队列研究。
J Microbiol Immunol Infect. 2023 Jun;56(3):506-515. doi: 10.1016/j.jmii.2023.03.004. Epub 2023 Mar 16.

引用本文的文献

1
Evaluation of the Effect of mRNA and Inactivated SARS-CoV-2 Vaccines on the Levels of Cytokines IL-2, IFN-γ, and Anti-RBD Spike SARS-CoV-2 Antibodies in People Living with HIV (PLHIV).评估mRNA疫苗和灭活新型冠状病毒疫苗对HIV感染者（PLHIV）体内细胞因子白细胞介素-2、干扰素-γ水平以及抗新型冠状病毒刺突蛋白受体结合域（RBD）抗体的影响。
Biomedicines. 2024 Sep 18;12(9):2115. doi: 10.3390/biomedicines12092115.
2
Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies.在致病性I型干扰素自身抗体触发和终身持续存在之前，就已出现免疫耐受丧失。
J Exp Med. 2024 Sep 2;221(9). doi: 10.1084/jem.20240365. Epub 2024 Jul 17.
3
Interferon Upregulation Associates with Insulin Resistance in Humans.干扰素上调与人类胰岛素抵抗相关。
Curr Diabetes Rev. 2025;21(3):86-105. doi: 10.2174/0115733998294022240309105112.
4
Role of autoantibodies targeting interferon type 1 in COVID-19 severity: A systematic review and meta-analysis.靶向1型干扰素自身抗体在新冠病毒疾病严重程度中的作用：一项系统评价与荟萃分析
J Transl Autoimmun. 2023 Oct 14;7:100219. doi: 10.1016/j.jtauto.2023.100219. eCollection 2023 Dec.
5
Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients.重症COVID-19患者中IFN-λ、IFN-γ及Toll样受体表达的变化
Microorganisms. 2023 Mar 8;11(3):689. doi: 10.3390/microorganisms11030689.

本文引用的文献

1
The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness.APOBEC 介导的 RNA 编辑在 SARS-CoV-2 突变、复制和适应性中的作用。
Sci Rep. 2022 Sep 13;12(1):14972. doi: 10.1038/s41598-022-19067-x.
2
Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity.来自 COVID-19 患者的抗 IFN-α/-ω 中和抗体与 IFN 反应下调和疾病严重程度的实验室生物标志物相关。
Eur J Immunol. 2022 Jul;52(7):1120-1128. doi: 10.1002/eji.202249824. Epub 2022 Apr 28.
3
AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection.艾滋病患者严重的 T 细胞耗竭后实现了对 SARS-CoV-2 感染的控制，但未清除。
Eur J Immunol. 2022 Feb;52(2):352-355. doi: 10.1002/eji.202149574. Epub 2021 Dec 4.
4
HIV and SARS-CoV-2 Co-Infection: What are the Risks?HIV与新型冠状病毒2型合并感染：有哪些风险？
Infect Drug Resist. 2021 Sep 28;14:3991-4014. doi: 10.2147/IDR.S277899. eCollection 2021.
5
Type I Interferons in COVID-19 Pathogenesis.1型干扰素在新冠病毒疾病发病机制中的作用
Biology (Basel). 2021 Aug 26;10(9):829. doi: 10.3390/biology10090829.
6
Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths.在 70 岁以上未感染的人群中，有 4%存在中和 I 型干扰素的自身抗体，占 COVID-19 死亡人数的 20%。
Sci Immunol. 2021 Aug 19;6(62). doi: 10.1126/sciimmunol.abl4340.
7
Human Immunodeficiency Virus/AIDS in the Era of Coronavirus Disease 2019: A Juxtaposition of 2 Pandemics.2019 年冠状病毒病时代的人类免疫缺陷病毒/艾滋病：两种大流行病的并置。
J Infect Dis. 2021 Nov 16;224(9):1455-1461. doi: 10.1093/infdis/jiab114.
8
Differentially expressed immune response genes in COVID-19 patients based on disease severity.基于疾病严重程度的 COVID-19 患者差异表达免疫反应基因。
Aging (Albany NY). 2021 Mar 29;13(7):9265-9276. doi: 10.18632/aging.202877.
9
COVID-19 Severity Index: A predictive score for hospitalized patients.COVID-19严重程度指数：住院患者的预测评分。
Med Intensiva (Engl Ed). 2020 Dec 29;46(2):98-101. doi: 10.1016/j.medin.2020.12.001.
10
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.COVID-19 危重症患者体内针对 I 型干扰素的自身抗体。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.

HIV-1 感染者住院治疗 COVID-19 时，中和抗体针对 I 型干扰素的频率较高。

High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19.

机构信息

Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy.

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161 Rome, Italy.

出版信息

Clin Immunol. 2022 Aug;241:109068. doi: 10.1016/j.clim.2022.109068. Epub 2022 Jun 25.

DOI:10.1016/j.clim.2022.109068
PMID:35764258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9233547/
Abstract

The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients.

摘要

在危重症 COVID-19 患者中已报道存在抗干扰素中和抗体（NAB）。我们发现，87.5%（7/8）合并 SARS-CoV-2 感染的 HIV-1 患者存在针对 IFN-α 亚型、IFN-β 和/或 IFN-ω 的血清抗 IFN-I NAB。在口咽样本中也检测到了抗 IFN-I NAB。NAB 阳性患者均为男性，高血清抗 IFN-α/ω NAB 滴度患者病情严重，并表现出 IFN 刺激基因表达减少。因此，高滴度的抗 IFN-α/ω NAB 可能导致 HIV-1 感染患者 COVID-19 病情更严重。